Sanara MedTech demonstrated strong revenue growth and improved profitability, driven by its core surgical business and strategic network expansion. However, the discontinuation of Tissue Health Plus and increased operating expenses pose challenges.
Company Guidance
During the Sanara MedTech third quarter of 2025 earnings call, the company outlined several key metrics and strategic decisions impacting its financial performance and future direction. The company achieved a net revenue of $26.3 million, marking a 22% year-over-year growth, with soft tissue repair product sales increasing by 24% to $23.4 million. Sanara also reported a $1 million improvement in net income from continuing operations and a $2.3 million enhancement in adjusted EBITDA, alongside a 200 basis point increase in gross margin to 93%. Despite these gains, the company announced the cessation of its Tissue Health Plus (THP) operations, a move expected to result in a cash investment between $5.5 million and $6.5 million in the second half of 2025, aligning with previously shared expectations. Looking ahead, Sanara anticipates high single-digit to low-teens revenue growth in the fourth quarter of 2025, excluding a $1.8 million headwind from the previous year's extraordinary demand for BIASURGE. The organization remains focused on driving sustainable growth, optimizing its commercial strategy, and leveraging its strong distributor network and clinical evidence to expand its market presence.
Strong Revenue Growth
Sanara MedTech's surgical team achieved net revenue of $26.3 million in Q3 2025, marking a 22% year-over-year growth, driven by soft tissue repair products.
Improved Profitability
The company reported a $1 million improvement in net income from continuing operations and a $2.3 million increase in adjusted EBITDA on net revenue growth of $4.7 million.
Expansion of Distributor Network
Sanara expanded its network from 300 to over 400 contracted distributors over the last 12 months, enhancing its market reach.
Clinical Evidence and New Product Initiatives
Two studies on CellerateRX were published in peer-reviewed journals, supporting its efficacy in complex surgical procedures. Progress was also made with the OsStic product under the BMI partnership.
Sanara MedTech (SMTI) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SMTI Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$28.04
$21.11
-24.71%
Aug 13, 2025
$27.47
$31.92
+16.20%
May 14, 2025
$35.10
$31.30
-10.83%
Mar 25, 2025
$35.69
$31.20
-12.58%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sanara MedTech (SMTI) report earnings?
Sanara MedTech (SMTI) is schdueled to report earning on Apr 01, 2026, Before Open (Confirmed).
What is Sanara MedTech (SMTI) earnings time?
Sanara MedTech (SMTI) earnings time is at Apr 01, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.